Alpha-1 MP

Phase 3Active
0 watching 0 views this week๐Ÿ“ˆ Rising
74
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pulmonary Emphysema in Alpha-1 PI Deficiency

Conditions

Pulmonary Emphysema in Alpha-1 PI Deficiency

Trial Timeline

Nov 1, 2013 โ†’ Jan 1, 2027

About Alpha-1 MP

Alpha-1 MP is a phase 3 stage product being developed by Grifols for Pulmonary Emphysema in Alpha-1 PI Deficiency. The current trial status is active. This product is registered under clinical trial identifier NCT01983241. Target conditions include Pulmonary Emphysema in Alpha-1 PI Deficiency.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (4)

NCT IDPhaseStatus
NCT02870348Phase 1/2Completed
NCT02870309Phase 1/2Completed
NCT02796937Phase 3Recruiting
NCT01983241Phase 3Active

Competing Products

20 competing products in Pulmonary Emphysema in Alpha-1 PI Deficiency

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
44
macitentan 10 mgBML, Inc.Phase 3
76
tadalafil + tadalafilEli LillyPhase 3
77
CS1 AdministrationCereno ScientificPhase 2
47
CS1Cereno ScientificPre-clinical
18
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
44
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
52
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
41
DS-9231 + PlaceboDaiichi SankyoPhase 2
52
RegadenosonAstellas PharmaPre-clinical
23
Reldesemtiv + PlaceboAstellas PharmaPhase 2
52
MonteplaseEisaiApproved
85
lysozyme 90 mg + PlaceboEisaiApproved
85
Prednisolone + VoriconazoleCiplaPhase 2/3
65
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)Eli LillyPhase 2
52
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
85